{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:58:46Z","timestamp":1793825926611,"version":"4.6.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitor therapy has become a promising option for the treatment of late-stage thymic epithelial tumors. In this manuscript, we presented a patient with metastatic thymoma administrated of anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab. Although the patient underwent a rapid and dramatic response to one dose of pembrolizumab, she suffered a storm of immune-therapy related toxicity events (irAEs), including liver and kidney dysfunction, hypothyroidism and myocarditis. We didn\u2019t observe &amp;gt;grade 3 irAEs, and proceed with pembrolizumab therapy after the function recovered. Although no guidelines recommend dose reduction of immunotherapy re-treating following initial irAEs, we optimize dose of pembrolizumab to minimize the irAEs induced by PD-1 antibody while maintaining clinical effectiveness. Excitingly, we observe remarkable tumor remission and mild toxicities of half dose of pembrolizumab in this case. In conclusion, the clinical utilization of immunotherapy is an encouraging therapeutic alternative for advanced thymomas. At the same time, patients have to be monitored very carefully, because of the risk to develop irAEs.<\/jats:p>","DOI":"10.3389\/fimmu.2021.621858","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T07:08:58Z","timestamp":1618470538000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report"],"prefix":"10.3389","volume":"12","author":[{"given":"Li","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qichun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2018.10.018","article-title":"Systemic treatments for thymoma and thymic carcinoma: A systematic review","volume":"126","author":"Berghmans","year":"2018","journal-title":"Lung Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.07.018","article-title":"Response to Pembrolizumab in a Patient with Relapsing Thymoma","volume":"11","author":"Zander","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000493187","article-title":"Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression","volume":"11","author":"Isshiki","year":"2018","journal-title":"Case Rep Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.01464","article-title":"Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade","volume":"38","author":"Betof Warner","year":"2020","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.08.005","article-title":"PD-1 checkpoint inhibition: Toxicities and management","volume":"35","author":"Hahn","year":"2017","journal-title":"Urol Oncol: Semin Orig Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.10.157","article-title":"Thymic tumors and immune checkpoint inhibitors","volume":"10","author":"Yokoyama","year":"2018","journal-title":"J Thorac Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.21037\/med.2018.03.17","article-title":"Thymic epithelial tumors and paraneoplastic autoimmune syndromes","volume":"2","author":"Szolkowska","year":"2018","journal-title":"Mediastinum"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000299","article-title":"Alterations of the immune system in thymic malignancies","volume":"9","author":"Weksler","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"107202","DOI":"10.1016\/j.carpath.2020.107202","article-title":"Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report","volume":"46","author":"Hardy","year":"2020","journal-title":"Cardiovasc Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.10.008","article-title":"Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma","volume":"21","author":"Hyun","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.3324\/haematol.2017.185777","article-title":"Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity","volume":"103","author":"Martinez-Calle","year":"2018","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e145186","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: Manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07741-0","article-title":"Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune Checkpoint Inhibitor Rechallenge after Immune-Related Adverse Events in Patients with Cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: Review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijc.33534","article-title":"Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer","author":"Low","year":"2021","journal-title":"Int J Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.621858\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T07:09:02Z","timestamp":1618470542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.621858\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2021.621858"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.621858","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"article-number":"621858"}}